Chad R Ritch
Overview
Explore the profile of Chad R Ritch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
69
Citations
1055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ajami T, Williams A, Ryan J, Prakash N, Khandekar A, Sureshkumar K, et al.
World J Urol
. 2025 Mar;
43(1):162.
PMID: 40072595
Purpose: Despite the growing adoption of HIFU treatment for localized prostate cancer (PC), standardized criteria for evaluating success and predicting recurrence remain undefined. Herein, we analyze the predictive value of...
2.
Egemba C, Kapil S, Ajami T, Williams A, Nahar B, Punnen S, et al.
Urol Oncol
. 2025 Feb;
PMID: 40021370
Introduction: Metabolic syndrome (MetS) has been associated with the pathogenesis of multiple solid tumors and chronic kidney disease (CKD) is related to higher incidence of urinary tract malignancy. Both MetS...
3.
Thomas J, Jain A, Hirpara R, Blachman-Braun R, Hougen H, Soodana-Prakash N, et al.
Clin Genitourin Cancer
. 2024 Dec;
23(1):102286.
PMID: 39732133
Objective: To assess the association of being overweight or obese with Nonmuscle invasive bladder cancer (NMIBC) recurrence, stage progression, and grade progression. Methods: Patients with NMIBC were included and categorized...
4.
Kimbel I, Wallaengen V, Zacharaki E, Breto A, Algohary A, Carbohn S, et al.
Acad Radiol
. 2024 Dec;
PMID: 39694787
Rationale And Objectives: Active surveillance (AS) is the preferred management strategy for low-risk prostate cancer. This study aimed to evaluate the impact of Habitat Risk Score (HRS), an automated approach...
5.
Ajami T, Yu H, Porto J, Prakash N, Williams A, Avda Y, et al.
Eur Urol Focus
. 2024 Dec;
PMID: 39665894
Background And Objective: Prostate cancer (PC) heterogeneity can result in sampling discrepancies during biopsy, leading to inaccurate molecular classifications that affect treatment decisions. We evaluated transcriptomic profile variability between multiparametric...
6.
Nahar B, Ajami T, Williams A, Prakash N, Khandekar A, Freitas P, et al.
Eur Urol Focus
. 2024 Nov;
PMID: 39613544
Background And Objective: Focal therapy is increasingly being used as a treatment for localized prostate cancer (PC). Our aim was to evaluate oncological outcomes, recurrence patterns, and survival after high-intensity...
7.
Freitas P, Blachman-Braun R, Soodana-Prakash N, Williams A, Ritch C, Punnen S, et al.
World J Urol
. 2024 Sep;
42(1):551.
PMID: 39347950
Purpose: Recent advancements in screening, prostate MRI, robotic surgery, and active surveillance have influenced the profile of patients undergoing radical prostatectomy (RP). We sought to examine their impact on trends...
8.
Hougen H, Reis I, Han S, Prakash N, Thomas J, Stoyanova R, et al.
Prostate Cancer Prostatic Dis
. 2024 Sep;
28(1):180-186.
PMID: 39333697
Background: 4Kscore is used to aid the decision for prostate biopsy, however its role in active surveillance (AS) has not been investigated in a magnetic resonance imaging (MRI)-based protocol. Our...
9.
Ajami T, Han S, Blachman-Braun R, Hougen H, Avda Y, Gonzalgo M, et al.
BJUI Compass
. 2024 Aug;
5(8):799-805.
PMID: 39157168
Objective: This study aims to investigate the impact of risk group classification, restaging transurethral resection (re-TURBT), and adjuvant treatment intensity on recurrence and progression risks in high-grade Ta tumours in...
10.
Ajami T, Blachman-Braun R, Porto J, Ritch C, Gonzalgo M, Punnen S, et al.
Urol Oncol
. 2024 May;
42(9):289.e1-289.e6.
PMID: 38789378
Objective: To assess the efficacy and safety of combined High-Intensity Focused Ultrasound (HIFU) and Holmium Laser Enucleation of the Prostate (HoLEP) in treating patients with both localized prostate cancer (PCa)...